In October, together with the Warsaw University of Life Sciences [SGGW], we are launching the new Polpharma Biologics...

Polpharma Biologics at IMPACT CEE

CEBioForum 2024 is an annual international conference for the biotechnology sector and also the largest industry even...

We are expanding our research portfolio - that's what you'll read about in Puls Biznesu. Editor Marcel Zatoński spoke...

Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars,...

Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars,...

Polpharma Biologics announces FDA approval of Tyruko® - first and only approved biosimi...

Polpharma Biologics, an international biotech company dedicated to the development and manufacture of biosimilars, an...

Amsterdam Munich, Zug – Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (...

3rd of August 2022 U.S. Food and Drug Administration (FDA) approves FYB201/CIMERLITM* (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®**  CIMERLI™ is the only biosimilar approved for all five Lucentis® indications  Commercially available in 0.3 mg and 0.5 mg dosages U.S. commercial launch by Coherus BioSciences, Inc. expected in early October 2022 Amsterdam, Munich,...